Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Current State of Affairs
View:
Post by oats on Oct 22, 2020 4:44pm

Current State of Affairs

It is pretty clear that the current state of affairs for the company could best be described as being in a state of flux.

This is not meant to be a negative statement, it simply puts everything into perspective as you are dealing with the PGX - YBG initiative that has likely turned other initiatives on their collective heads.  Once again, not in a bad way but in a good way.  

What this brings into play is that the use of Beta Glucan may be limited to the base business, at least in the intermediate term until the BG Clincal Study can be proven out.  Other initiatives may find themselves using different and more efficient polymers that achieve greater results.  This is what new discoveries do to the research side of the street.  Ceapro has made great strides and continues to ramp up the game as they discover new processes.  

Now, what does this do to the "Ceapro Story"?  Great question I must say.  At this time, only Gilles Gagnon and team, including McMaster, know the answer to that question and justifiablly so.  When I spoke to Jenene Thomas yesterday, she indicated that she has no new updates to provide and any question that I asked her was met with disclosure issues.  I don't agree with all of them, I think the term "disclosure" used by her is more of an excuse than anything else but I have to respect her stance.

This scenario has very much delayed the "promised" Ceapro PGX Strategy that was due mid-year.  I get it, there have been improvments due to discovery and science.  This clearly has changed the "Ceapro Story" from where it was a year ago but what this also means is that all the IB's that were presented to in the past are now due for updates whenever that may be.  Are some closer to the new story vs others, such as HCW?  Another great question.  Don't forget that Cosme Ordonez is likely a very interested spectator.  However, and for now, the bottom line is that you still have very little speculation coming out of the US in the form of early buying or expectation of certainty in the short to medium term.  However, that is not the way that Gilles Gagnon operates.  He is looking to solidyfy the results so that certainty can and will be achieved.  Are we far a way from that?  I don't think so and today's news points further to solidifying the short term.  

What all of this points to from the seat that I sit in is that Ceapro IR is pretty much dormant because they have no update or current story to push, I could be wrong but that was the inference that I got yesterday.  You have seen a marked deterioration in the US buying or volume so that tells me that Jenene is either on hold or she has been unsuccessful in gaining  the ear of the smart money.  Once again, I could be wrong but I think we are all left to the same guessing game.  

The bottom line?  Gilles Gagnon has never been one to be pushed to say something before it is time, no different this time around.  However, a news relase can take on many meanings if one wants to read between the lines.

As far as I am concerned, Ceapro has a significant discovery and knows it.  The Company is simply trying to process the data and push to the next level which will likely be very substantial, It will happen.
Comment by Ciao on Oct 22, 2020 4:56pm
Oats are you thinking that PGX capacity will be directed towards Y BG and thus taken away from the output from a PGX deal? If that is the direction then PGX has a good chance of being in the driver's seat and in essence going it alone. "This scenario has very much delayed the "promised" Ceapro PGX Strategy that was due mid-year. "
Comment by oats on Oct 22, 2020 5:16pm
Ciao, Great question but I don't want to speculate on this. What I do know is that Gilles Gagnon is a very smart and process driven leader.  I would suggest that he is gaining the upper hand here and is well ahead of this.  If it was a dud, we would know it.  Sorry that I cannot add more substance.
Comment by prophetoffacts on Oct 22, 2020 5:24pm
This post has been removed in accordance with Community Policy
Comment by oats on Oct 22, 2020 5:37pm
proph, I will be happy to wait for the formal and much more detailed forthcoming PGX strategy.
Comment by trek01 on Dec 21, 2020 1:13pm
Just want to bring the original post up again. Oats would you have any updates for us?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities